It could get interesting if RAC's preclinical for Melanoma evaluates Zantrene in combination with multiple PD-1 inhibitors as speculated by others here on HC before. Whilst a preclinical study is not a clinical trial the results could prove interesting. I wonder if RAC would try a number of PD-1s in their clinical trial - would require multiple arms in the trial.
From the above, the below is a comment by one of the top FDA Cancer Doctors in the New England Journal of medicine.
https://endpts.com/uncoordinated-an...nhibitor-developers-for-creating-a-wild-west/
The timing could be spectacularly perfect ... and I hope RAC make the most of it in terms of fine-tuning and discussing their plans.
Industry news, page-438
-
- There are more pages in this discussion • 1,332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.76 |
Change
0.050(2.92%) |
Mkt cap ! $311.6M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $697.2K | 375.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2247 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3000 | 1 |
View Market Depth
| Last trade - 12.43pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |